These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16438641)

  • 21. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples.
    Venturi G; Catucci M; Romano L; Corsi P; Leoncini F; Valensin PE; Zazzi M
    J Infect Dis; 2000 Feb; 181(2):740-5. PubMed ID: 10669367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naïve HIV-infected patients.
    Clevenbergh P; Cua E; Dam E; Durant J; Schmit JC; Boulme R; Cottalorda J; Beyou A; Schapiro JM; Clavel F; Dellamonica P
    HIV Clin Trials; 2002; 3(1):36-44. PubMed ID: 11819184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution.
    Kantor R; Katzenstein D
    AIDS Rev; 2003; 5(1):25-35. PubMed ID: 12875105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. pol gene diversity of five human immunodeficiency virus type 1 subtypes: evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D.
    Cornelissen M; van den Burg R; Zorgdrager F; Lukashov V; Goudsmit J
    J Virol; 1997 Sep; 71(9):6348-58. PubMed ID: 9261352
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Co-circulation HIV-1 subtypes B, C, and CRF31_BC in a drug-naïve population from Southernmost Brazil: analysis of primary resistance mutations.
    de Medeiros RM; Junqueira DM; Matte MC; Barcellos NT; Chies JA; Matos Almeida SE
    J Med Virol; 2011 Oct; 83(10):1682-8. PubMed ID: 21837783
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B.
    Grossman Z; Vardinon N; Chemtob D; Alkan ML; Bentwich Z; Burke M; Gottesman G; Istomin V; Levi I; Maayan S; Shahar E; Schapiro JM;
    AIDS; 2001 Aug; 15(12):1453-60. PubMed ID: 11504976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Surveillance of HIV type 1 drug resistance among naive patients from Venezuela.
    Castillo J; Comegna M; Quijada W; Jauvin V; Pinson P; Masquelier B; Fleury H; Castro E
    AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1329-33. PubMed ID: 19954301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals.
    Simon V; Vanderhoeven J; Hurley A; Ramratnam B; Louie M; Dawson K; Parkin N; Boden D; Markowitz M
    AIDS; 2002 Jul; 16(11):1511-9. PubMed ID: 12131189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Presence of drug resistance mutations among drug-naive patients in Morocco.
    Annaz HE; Recordon-Pinson P; Baba N; Sedrati O; Mrani S; Fleury H
    AIDS Res Hum Retroviruses; 2011 Aug; 27(8):917-20. PubMed ID: 21087198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1.
    Richard N; Juntilla M; Abraha A; Demers K; Paxinos E; Galovich J; Petropoulos C; Whalen CC; Kyeyune F; Atwine D; Kityo C; Mugyenyi P; Arts EJ
    AIDS Res Hum Retroviruses; 2004 Apr; 20(4):355-64. PubMed ID: 15157354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
    Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
    Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
    Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
    J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV-1 primary and secondary antiretroviral drug resistance and genetic diversity among pregnant women from central Brazil.
    Cardoso LP; Pereira GA; Viegas AA; Schmaltz LE; Stefani MM
    J Med Virol; 2010 Mar; 82(3):351-7. PubMed ID: 20087934
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV-1 drug resistant mutations in chronically infected treatment naive individuals in the pre-ARV era in Nigeria.
    Odaibo GN; Ola SO; Landerz M; Dietrich U; Olaleye DO
    Afr J Med Med Sci; 2012 Dec; 41 Suppl():61-3. PubMed ID: 23678638
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
    Mo H; King MS; King K; Molla A; Brun S; Kempf DJ
    J Virol; 2005 Mar; 79(6):3329-38. PubMed ID: 15731227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Rate of genotypic mutations and resistance to antiretroviral drugs in a general hospital].
    Fernández Lisón LC; Fernández Pereira LM; Romero Chala S
    Farm Hosp; 2011; 35(4):191-6. PubMed ID: 21087876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of HIV-1 isolates from antiretroviral drug-naive children in southern India.
    Soundararajan L; Karunaianandham R; Jauvin V; Schrive MH; Ramachandran R; Narayanan PR; Fleury HJ; Swaminathan S
    AIDS Res Hum Retroviruses; 2007 Sep; 23(9):1119-26. PubMed ID: 17919107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Limited increase in primary HIV-1C drug resistance mutations in treatment naïve individuals in Ethiopia.
    Huruy K; Maier M; Mulu A; Liebert UG
    J Med Virol; 2015 Jun; 87(6):978-84. PubMed ID: 25649964
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir.
    Ananworanich J; Hirschel B; Sirivichayakul S; Ubolyam S; Jupimai T; Prasithsirikul W; Chetchotisakd P; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; Schutz M; Snowden W; Ruxrungtham K;
    Antivir Ther; 2006; 11(5):631-5. PubMed ID: 16964832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.